Overview
Enzo
For Enzo Biochem, genomic research is the key to both diagnostic and therapeutic care. The biotech company is focused on the development and sale of gene-based tests and pharmaceuticals through its three operating divisions. The Enzo Clinical Labs unit provides diagnostic testing services in the New York City area, while Enzo Life Sciences makes reagents used in research by pharmaceutical firms, biotech companies, academic institutions.
...
Read More The third division, Enzo Therapeutics, is a development-stage firm working to treat ophthalmic conditions, gastrointestinal ailments, and other diseases.
Read Less
Read More The third division, Enzo Therapeutics, is a development-stage firm working to treat ophthalmic conditions, gastrointestinal ailments, and other diseases.
Read Less
Kara Cannon
See more contacts
Scientific Research and Development Services
,
Medical and Diagnostic Laboratories
,
Professional, Scientific, and Technical Services
,
Commercial physical research
,
Biotechnical research, commercial
See All Industries Biological laboratory
See Fewer Industries
See All Industries Biological laboratory
See Fewer Industries
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
?
?
Actual
?
Actual
$31.91 million
Actual
2.72%
$85
JUL
?
?
NYSE:ENZ
Contacts
Get in Touch with 4 Principals* and 48 Contacts
-
Kara CannonChief Executive Officer
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of July 31, 2024 (12 month period) in USD
Annual Revenue 2024
$31.91 million
USD
Actual
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | -$26 | -$37 | -$17 |
| Net Investing Cash | -$1 | $99 | $25 |
| Net Financing Cash | -$4 | -$1 | -$0 |
| Net Change in Cash | -$31 | $61 | $8 |
| Cash at Beginning of Period | $83 | $23 | $14 |
| Cash at End of Period | $52 | $83 | $23 |
| Capital Expenditure | -$1 | -$3 | -$3 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $52 | $82 | $22 |
| Accounts Receivable | $4 | $5 | $5 |
| Inventories | $7 | $8 | $10 |
| Other Current Assets | $7 | $3 | $7 |
| Asset Summary | |||
| Total Current Assets | $70 | $98 | $43 |
| Tangible Fixed Assets | $15 | $17 | $16 |
| Intangible Assets | $ | $ | $ |
| Total Assets | $86 | $122 | $76 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $1 | $4 | $4 |
| Short-Term Debt | $0 | $3 | $0 |
| Other Current Liabilities | $23 | $34 | $9 |
| Liability Summary | |||
| Total Current Liabilities | $25 | $40 | $13 |
| Long-Term Debt | $0 | $0 | $4 |
| Other Long-Term Liabilities | $ | $ | $ |
| Total Liabilities | $30 | $43 | $21 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $1 | $0 | $0 |
| Retained Earnings | -$294 | -$268 | -$289 |
| Equity Summary | |||
| Total Equity | $56 | $78 | $54 |
| Shares Outstanding | 52,244,074 | 49,997,631 | 48,720,454 |